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In recent years, numerous studies have 
been performed to identify biomarkers that 
predict prognosis or response to chemother-
apy of carcinomas (Suzuki et al., 2011; Van 
Schaeybroeck et al., 2011; Micke et al., 
2003; Reis-Filho and Pusztai, 2011; Marchan 
2012, 2014). Non-small cell lung cancer re-
presents one example where expression pro-
filing was used to successfully identify prog-
nostic signatures (Wigle et al., 2002; Tomida 
et al., 2004; Roepman et al., 2009; Chen et 
al., 2007; Larsen et al., 2007; Lu et al., 2006; 
Guo et al., 2008), with the overall goal to 
assist in the decision whether patients should 
receive adjuvant chemotherapy after surgical 
resection. A recently published meta-
analysis based on gene expression microar-
ray data from five lung cancer cohorts 
(n=860 patients) identified 14 genes as sig-
nificantly associated with survival (Botling 
et al., 2013). Using a multiplex real-time 
PCR-based assay followed by validation on 
diagnostic paraffin embedded patient tissue, 
two further studies established gene signa-
tures based on the combination of a few 
genes that robustly predict prognosis in the 
clinically-important stage I non-small lung 
cancer subgroup (Kratz et al., 2012; Wistuba 
et al., 2013). Gene expression studies have 
also been performed in breast cancer (re-
view: Schmidt et al., 2009; Hellwig et al., 
2010), and most of the identified prognostic 
genes are proliferation-associated (Schmidt 
et al., 2008; Siggelkow et al., 2012) or indi-
cate immune cell infiltration (Schmidt et al., 
2012; Chen et al., 2012; Godoy et al., 2014). 
However, redox factors (Cadenas et al., 
2010), anti-apoptotic proteins (Petry et al., 
2010), and cytoskeletal factors controlling 
mechanoreactivity and migration (Martin et 
al., 2012) have also been identified.  
A major challenge facing physicians 
when deciding on the best course of treat-
ment for their patients is the suboptimal ac-
curacy of prognostic markers (Schmidt et al., 
2009). For example, in node-negative breast 
cancer only approximately 30 % of all pa-
tients will go on to develop metastasis 
(Cianfrocca and Goldstein, 2004). However, 
the majority of patients receive chemothera-
py. Therefore, biomarkers are urgently need-
ed that accurately predicts the 70 % of pa-
tients who do not require chemotherapy be-
cause they will never develop metastasis. 
Although numerous biomarkers are signifi-
cantly associated with the risk of metastasis, 
the accuracy of prediction is not sufficient to 
convince physicians and patients to waive 
chemotherapy.  
Despite the unsatisfactory situation in 
predicting prognosis, many scientists have 
shifted their focus to understand whether the 
biomarkers identified in expression profiling 
can be used as therapeutic targets. Ideally, 
the best candidate genes would be expressed 
specifically in carcinomas and not in healthy 
tissues. A further advantage would be that 
these genes are expressed on the plasma 
membrane of tumor cells, such as ERBB2 
(Brase et al., 2010) or Ep-CAM (Schmidt et 
al., 2011), making them the good targets for 
therapeutic antibodies. Such membranous 
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protein targets were recently described in 
both pancreatic and non-small cell lung can-
cer (Wöll et al., 2014; Micke et al., 2014). 
Claudins, for example are central compo-
nents of tight junctions that regulate epitheli-
al barrier function, and are frequently dereg-
ulated during tumorigenesis (Ding et al., 
2013; Kwon, 2013; Runkle and Mu, 2013). 
Based on gene expression profiles and im-
munohistochemistry, Micke et al. (2014) 
identified that claudin 6 and the splice vari-
ant 2 of claudin 18, were strongly overex-
pressed in minor subsets of non-small cell 
lung cancer patients. In addition, high ex-
pression of claudin 6 was associated with 
worse prognosis. Antibodies against claudin 
18.2 showed promising results in clinical 
phase I/II trials (Schuler et al., 2013) and 
claudin 6-antibodies have just entered clini-
cal trials for ovarian cancer. Thus, such tar-
geted therapy may present a valuable option, 
also in selected lung cancer patients. Wheth-
er the success story of trastuzumab for ErB2 
positive breast carcinomas can be repeated 
for further membrane proteins that are over-
expressed in subsets of carcinomas is high 
on the watch list of all scientists and physi-
cians in this field of research. 
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